Table 2 Baseline patient comorbidities
OTX-101 n = 1846 | CsA n = 2248 | LFT n = 3008 | |
|---|---|---|---|
Quan-CCI, n (%) | |||
Mean ± SD | 0.7 ± 1.4 | 1.2 ± 1.8 | 1.0 ± 1.7 |
Median (IQR) | 0.0 (0.0, 1.0) | 0.0 (0.0, 2.0) | 0.0 (0.0, 2.0) |
Score 0 | 1199 (65.0) | 1128 (50.2) | 1670 (55.5) |
Score 1–2 | 513 (27.8) | 729 (32.4) | 926 (30.8) |
Score 3–4 | 90 (4.9) | 258 (11.5) | 276 (9.2) |
Score ≥ 5 | 44 (2.4) | 133 (5.9) | 136 (4.5) |
Other comorbiditiesa, n (%) | |||
Eye-related comorbidities | 449 (24.3) | 466 (20.7) | 652 (21.7) |
Blepharitis | 264 (14.3) | 240 (10.7) | 323 (10.7) |
Visual disturbance | 154 (8.3) | 185 (8.2) | 251 (8.3) |
Allergic conjunctivitis | 99 (5.4) | 97 (4.3) | 158 (5.3) |
Major autoimmune disorders | 52 (2.8) | 96 (4.3) | 85 (2.8) |
Rheumatoid arthritis | 52 (2.8) | 96 (4.3) | 85 (2.8) |
Any other comorbidities | 722 (39.1) | 1146 (51.0) | 1427 (47.4) |
Thyroid disease | 288 (15.6) | 485 (21.6) | 578 (19.2) |
Anxiety | 277 (15.0) | 478 (21.3) | 619 (20.6) |
Depression | 234 (12.7) | 450 (20.0) | 534 (17.8) |
Fatigue | 204 (11.1) | 298 (13.3) | 430 (14.3) |
Menopause | 121 (6.6) | 163 (7.3) | 235 (7.8) |
Systemic lupus | 47 (2.5) | 68 (3.0) | 112 (3.7) |
Medicationsb, n (%) | |||
Antidepressant and anti-anxiety medication | 861 (46.6) | 1398 (62.2) | 1768 (58.8) |
Eye-related medication | 823 (44.6) | 560 (24.9) | 829 (27.6) |
CsA | 293 (15.9) | 241 (8.1) | |
LFT | 236 (12.8) | 117 (5.2) | |
Other eye-related medication | 474 (25.7) | 473 (21.1) | 646 (21.5) |
High blood pressure medication | 748 (40.5) | 1201 (53.1) | 1470 (48.9) |
Hormone replacement therapy | 473 (25.6) | 707 (31.5) | 839 (27.9) |
Topical glaucoma medication | 191 (10.3) | 200 (8.9) | 300 (10.1) |
Topical allergy medication | 162 (8.8) | 220 (9.8) | 290 (9.6) |